Results 271 to 280 of about 1,315,164 (344)

Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors. [PDF]

Ther Adv Med Oncol
Hsu R, Resnick K, Zang P, Larsen T, Ye S, Choi A, Yu S, Brady K, Angell TE, Dara L, Ito F, Nieva JJ, In GK.   +12 more
europepmc   +1 more source

All Men Free and Brethren. Essays on the History of African American Freemasonry. Edited by Peter P. Hinks and Stephen Kantrowitz. Foreword by Leslie A. Lewis. Ithaca, US and London: Cornell University Press, 2013. 262 pages. ISBN-10: 0-8014-5030-6; ISBN-13: 978-0-8014-5030-3.

, 2015
Cécile Révauger
openalex   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

A Critical Review of Post-Childbirth Pain Experiences and Management in Relation to Postpartum Depression Risk for Racial and Ethnic Minorities. [PDF]

Curr Psychiatry Rep
Lara-Cinisomo S, Beeram S, Romero ME.
europepmc   +1 more source

Black Literary Suite: Histories of African American Short Stories: a Digital Humanities Exhibit

, 2015
Kenton Rambsy, Jeremiah Carter
openalex   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Relationships Between Trauma Exposure, PTSD, and Formal Help-Seeking in African American and Latina Women Sexual Assault Survivors. [PDF]

Aggress Violent Behav
Ullman SE.
europepmc   +1 more source

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Effects of Childhood Police Contact on Adolescent Suicidality: A Propensity Score Matched Analysis. [PDF]

Res Child Adolesc Psychopathol
Schiff SJ, Meza J, Lee SS.
europepmc   +1 more source

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study

Arthritis &Rheumatology, Accepted Article.
Objective Evaluate the efficacy and safety of guselkumab, an interleukin‐23p19‐subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor inhibitor (TNFi‐IR).
Alexis Ogdie, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B Gottlieb   +12 more
wiley   +1 more source